Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2019 from OUS - Section for Cellular Therapy

9 publications found

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053

Kyte JA, Fåne A, Pule M, Gaudernack G (2019)
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
Oncoimmunology, 8 (4), e1565236
DOI 10.1080/2162402X.2019.1565236, PubMed 30906659

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S (2019)
Treating osteosarcoma with CAR T cells
Scand J Immunol, 89 (3), e12741
DOI 10.1111/sji.12741, PubMed 30549299

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S (2019)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, Olsen CE, Wälchli S, Inderberg EM, Kubin A, Peng Q, Berg K (2019)
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy
NPJ Breast Cancer, 5, 13
DOI 10.1038/s41523-019-0108-8, PubMed 30993194

 
Page visits: 222075